JP2005537028A5 - - Google Patents

Download PDF

Info

Publication number
JP2005537028A5
JP2005537028A5 JP2004549835A JP2004549835A JP2005537028A5 JP 2005537028 A5 JP2005537028 A5 JP 2005537028A5 JP 2004549835 A JP2004549835 A JP 2004549835A JP 2004549835 A JP2004549835 A JP 2004549835A JP 2005537028 A5 JP2005537028 A5 JP 2005537028A5
Authority
JP
Japan
Prior art keywords
hpv16
column
guu
snip
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004549835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005537028A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/020340 external-priority patent/WO2004002416A2/en
Publication of JP2005537028A publication Critical patent/JP2005537028A/ja
Publication of JP2005537028A5 publication Critical patent/JP2005537028A5/ja
Withdrawn legal-status Critical Current

Links

JP2004549835A 2002-06-26 2003-06-26 ヒト乳頭腫ウイルス感染症を治療する方法及び材料 Withdrawn JP2005537028A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39179502P 2002-06-26 2002-06-26
US41799702P 2002-10-14 2002-10-14
US44906603P 2003-02-21 2003-02-21
PCT/US2003/020340 WO2004002416A2 (en) 2002-06-26 2003-06-26 Methods and materials for treating human papillomavirus infections

Publications (2)

Publication Number Publication Date
JP2005537028A JP2005537028A (ja) 2005-12-08
JP2005537028A5 true JP2005537028A5 (https=) 2006-01-26

Family

ID=30003830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004549835A Withdrawn JP2005537028A (ja) 2002-06-26 2003-06-26 ヒト乳頭腫ウイルス感染症を治療する方法及び材料

Country Status (6)

Country Link
US (1) US7704965B2 (https=)
EP (1) EP1539245A2 (https=)
JP (1) JP2005537028A (https=)
AU (1) AU2003256325A1 (https=)
CA (1) CA2491034A1 (https=)
WO (1) WO2004002416A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2365901A1 (en) 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
WO2005017127A2 (en) * 2003-02-21 2005-02-24 The Penn State Research Foundation Rna interference compositions and methods
WO2007121893A1 (en) * 2006-04-21 2007-11-01 Transgene S.A. Method for treating hpv infected patients
CA2712056C (en) 2007-01-16 2016-06-21 The University Of Queensland Method of inducing an immune response
CA2619157A1 (en) * 2007-02-08 2008-08-08 Michel Serrano Anti-human papillomas virus composition
US7973211B2 (en) * 2007-04-18 2011-07-05 Kao Corporation Animal model for hyperpigmentation
US7897833B2 (en) * 2007-04-18 2011-03-01 Kao Corporation Animal model for pigment spots
JP6153866B2 (ja) 2010-05-25 2017-06-28 キアゲン ガイサーズバーグ アイエヌシー． 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ
WO2012016139A2 (en) * 2010-07-29 2012-02-02 Sirnaomics, Inc. Sirna compositions and methods for treatment of hpv and other infections
CN102228698B (zh) * 2011-06-28 2013-12-18 广西医科大学附属肿瘤医院 Hpv58型治疗性复合基因疫苗及其构建方法
AU2012298125B2 (en) 2011-08-19 2015-09-24 Immortal Spirit Limited Antibody and antibody-containing composition
CN104404076B (zh) * 2014-11-04 2017-10-03 珠海雅马生物工程有限公司 利用锌指核酸酶敲除人乳头瘤病毒e6e7基因的方法
WO2017214449A1 (en) * 2016-06-09 2017-12-14 The Regents Of The University Of California Inhibition of e5 in hpv-infected cells
GB201817990D0 (en) * 2018-11-02 2018-12-19 Univ Of Essex Enterprise Limited Enzymatic nucleic acid molecules

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511713A (en) 1980-11-12 1985-04-16 The Johns Hopkins University Process for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
DE3280400D1 (de) 1981-10-23 1992-06-04 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
FR2536278A1 (fr) 1982-11-18 1984-05-25 Dupont Michele Nouvelle composition therapeutique utile notamment pour la cicatrisation des plaies
NZ209840A (en) 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5272065A (en) 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4740463A (en) 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
CA1276575C (fr) 1984-11-30 1990-11-20 Sylvie Beaudenon Sondes a papillomavirus et procede de diagnostic in vitro d'infections a papillomavirus
US5411857A (en) 1985-07-31 1995-05-02 Institut Nationale De La Sante Probes for papillomaviruses and an in vitro diagnostic procedure for papilloma infections
US5876922A (en) 1985-07-31 1999-03-02 Institute Pasteur Papillomavirus probe and a process for in vitro diagnosis of papillomavirus infections
JP2648303B2 (ja) 1985-04-04 1997-08-27 ジョージタウン・ユニバーシティ 型特異的乳頭腫ウイルスｄｎａ配列およびペプチド
ATE76429T1 (de) 1986-03-21 1992-06-15 Pasteur Institut Bestimmte, von einem papillomavirus-genom abgeleitete dns-sequenzen, deren anwendungen fuer in vitro-diagnostische zwecke und die herstellung von antigenzusammensetzungen.
US5071757A (en) 1986-10-06 1991-12-10 Kreider John W Methods for propagating fastidious human viruses and for producing purified suspensions thereof
US4814268A (en) 1986-10-06 1989-03-21 Kreider John W Methods for propagating fastidious human viruses and for producing purified suspensions thereof
US4849332A (en) 1987-05-26 1989-07-18 Life Technologies, Inc. Human papillomavirus 35 nucleic acid hybridization probes and methods for employing the same
US4849331A (en) 1987-06-09 1989-07-18 Life Technologies, Inc. Human papillomavirus 44 nucleic acid hybridization probes and methods for employing the same
US4849334A (en) 1987-06-09 1989-07-18 Life Technologies, Inc. Human papillomavirus 43 nucleic acid hybridization probes and methods for employing the same
US4908306A (en) 1987-06-12 1990-03-13 Life Technologies, Inc. Human papillomavirus 56 nucleic acid hybridization probes and methods for employing the same
DE3722968A1 (de) 1987-07-11 1989-01-19 Behringwerke Ag Humaner papillomvirus typ 41, seine dna und die dafuer kodierenden proteine
FR2629458B2 (fr) 1987-07-31 1991-08-09 Ire Celltarg Sa Nouvelles sondes d'acides nucleiques specifiques de differents types de virus de papillome humain
CA1339596C (en) 1987-08-07 1997-12-23 New England Medical Center Hospitals, Inc. Viral expression inhibitors
ATE151467T1 (de) 1987-11-30 1997-04-15 Univ Iowa Res Found Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
FR2632956B2 (fr) 1988-05-13 1991-07-12 Pasteur Institut Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus
DE3826793A1 (de) 1988-08-06 1990-03-08 Behringwerke Ag Humaner papillomvirus typ 57, seine dna und die davon kodierten proteine
CA1339729C (en) 1988-10-26 1998-03-17 Wayne D. Lancaster Human papillomavirus type 52 dna sequences and methods for employing thesame
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5776502A (en) 1989-07-18 1998-07-07 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression
IT1232318B (it) 1989-09-07 1992-01-28 Crinos Industria Farmaco Composizioni ad uso topico contenenti acidi nucleici depolimerizzati per la cosmesi della pelle e del corpo.
US5053024A (en) * 1989-10-23 1991-10-01 Israel Dvoretzky Application system and method for treating warts
US6174870B1 (en) * 1989-12-04 2001-01-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of papillomavirus
US5811232A (en) 1989-12-04 1998-09-22 Isis Pharmaceuticals, Inc. Oligonucleotides for Papillomavirus
US5756282A (en) 1989-12-04 1998-05-26 Isis Pharmaceuticals, Inc. Oligonucleotides for the diagnosis of papillomavirus
US5457189A (en) 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
CA2052413C (en) 1990-09-28 2004-07-13 Jeffrey L. Joseph Nucleotides sequences useful as type-specific probes, pcr primers and lcr probes for the amplifications and detection of human papilloma virus, and related kits and methods
FR2670797A1 (fr) 1990-12-20 1992-06-26 Pasteur Institut Sequences d'adn determinees derivees du genome du papillomavirus hpv39, application de ces sequences au diagnostic in vitro d'infection par ce papillomavirus, et a la production de composition immunogene.
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
FR2678284B1 (fr) 1991-06-28 1993-10-08 Pasteur Institut Sequences d'adn derivees du genome du papillomavirus hpv42, application de ces sequences au diagnostic in vitro d'infection par ce papillomavirus et a la production de compositions immunogenes.
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5470577A (en) 1993-07-07 1995-11-28 Trustees Of Boston University Stimulation of tanning by DNA fragments or single-stranded DNA
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
KR100332250B1 (ko) 1993-09-24 2002-12-05 이. 가브릴로프 알렉산더 2',5'-올리고아데닐레이트2',3'-시클로포스페이트
CA2176256A1 (en) 1993-11-16 1995-05-26 Lyle John Arnold, Jr. Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages
NZ276968A (en) 1993-11-16 1998-04-27 Genta Inc Synthetic oligomers enriched for phosphonate internucleosidyl linkages of preselected chirality and their preparation
WO1995013833A1 (en) 1993-11-16 1995-05-26 Genta Incorporated Synthetic oligomers having phosphonate internucleosidyl linkages of undefined chirality mixed with non-phosphonate internucleosidyl linkages
US5955597A (en) 1993-11-16 1999-09-21 Genta, Incorporated Chirally enriched synthetic phosphate oligomers
US6060456A (en) 1993-11-16 2000-05-09 Genta Incorporated Chimeric oligonucleoside compounds
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US6075012A (en) 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
WO1995028942A1 (en) 1994-04-26 1995-11-02 Genta Incorporated Antisense oligomers for inhibiting human papillomaviruses
DE4415743C2 (de) 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5543417A (en) 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5627159A (en) 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
US5807718A (en) * 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
PT799058E (pt) 1994-12-24 2003-11-28 Univ Cambridge Tech Melhoramentos na funcao endometrica ou com ela relacionados
EP0874910A4 (en) 1995-06-07 1999-04-21 Life Technologies Inc ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5821050A (en) 1995-07-04 1998-10-13 Isis Pharmaceuticals, Inc. Drug screening assay for antiviral activity against papillomavirus
FR2737118B1 (fr) 1995-07-28 1997-09-05 Oreal Composition dermatologique ou pharmaceutique, procede de preparation et utilisation
US5824519A (en) 1995-11-08 1998-10-20 Medical University Of South Carolina Tissue-specific and target RNA-specific ribozymes
JP2000505418A (ja) 1996-01-26 2000-05-09 コドン・ファーマシューティカルズ・インコーポレイテッド オリゴヌクレオチド類縁体
US5981173A (en) 1996-02-14 1999-11-09 Institut Pasteur Genital human papillomavirus type 68a (HPV-68a), related to the potentially oncogenic HPV-39
US6022863A (en) 1996-05-21 2000-02-08 Yale University Regulation of gene expression
WO1998004575A2 (en) 1996-07-31 1998-02-05 Gilead Sciences, Inc. Lipophilic oligonucleotide analogs
WO1998037240A1 (en) 1997-02-24 1998-08-27 Tm Technologies, Inc. Anti-sense oligonucleotide pharmacological agents
US6084090A (en) 1997-09-05 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Human papilloma virus anti-sense oligonucleotides
WO1999014377A2 (en) 1997-09-16 1999-03-25 Innogenetics N.V. Detection and identification of human papillomavirus by pcr and type-specific reverse hybridization
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6087341A (en) 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
AU762405B2 (en) * 1998-04-29 2003-06-26 Medac Gesellschaft Fur Klinische Spezialpraparate Mbh Treatment of papilloma virus infection using a mycobacterium
AU5298699A (en) * 1998-08-13 2000-03-06 Johnson & Johnson Research Pty. Limited Dnazymes and methods for treating hpv-related disorders
SI1108035T1 (sl) 1998-09-04 2007-12-31 Sanofi Pasteur Ltd Zdravljenje raka materničnega vratu
EP1151094A1 (en) 1998-12-07 2001-11-07 University College London Cervical cancer treatment
CA2361201A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
AU4028800A (en) 1999-04-02 2000-10-23 City Of Hope Method for identifying accessible binding sites on rna
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
CA2365901A1 (en) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
CA2429814C (en) * 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
US20040209263A1 (en) * 2000-12-07 2004-10-21 Clawson Gary A. Selection of catalytic nucleic acids targeted to infectious agents
JP2004535813A (ja) * 2001-07-17 2004-12-02 ミルナー，アン，ジョセフィーヌ 遺伝子発現のサイレンシング
US6821523B2 (en) * 2002-06-21 2004-11-23 Dermatrends, Inc. Topical administration of pharmacologically active bases in the treatment of warts
WO2005017127A2 (en) * 2003-02-21 2005-02-24 The Penn State Research Foundation Rna interference compositions and methods

Similar Documents

Publication Publication Date Title
Montiel-Gonzalez et al. Current strategies for site-directed RNA editing using ADARs
JP2021048882A5 (https=)
AU683011B2 (en) Enzymatic RNA molecules
Saneyoshi et al. A general method for the synthesis of 2 ‘-O-cyanoethylated oligoribonucleotides having promising hybridization affinity for DNA and RNA and enhanced nuclease resistance
CA3233336A1 (en) Circular rna and preparation method thereof
JP4001624B2 (ja) Ｄｎａ酵素分子
AU717736B2 (en) Catalytic nucleic acid and its medical use
JP2005537028A5 (https=)
JP2009516512A5 (https=)
EP3216870A1 (en) Riboregulator compositions and methods of use
JP2005501557A5 (https=)
CA2173361A1 (en) Antisense oligonucleotide generators
Wilds et al. Duplex Recognition by Oligonucleotides Containing 2 ‘-Deoxy-2 ‘-fluoro-d-arabinose and 2 ‘-Deoxy-2 ‘-fluoro-d-ribose. Intermolecular 2 ‘-OH− Phosphate Contacts versus Sugar Puckering in the Stabilization of Triple-Helical Complexes
CN116121246A (zh) 一种新型小激活rna
JP2005511055A5 (https=)
Zaghloul et al. Optimizing anti-gene oligonucleotide ‘Zorro-LNA’for improved strand invasion into duplex DNA
Lutzelberger et al. A novel splice donor site in the gag-pol gene is required for HIV-1 RNA stability
US20040220130A1 (en) Compact synthetic expression vector comprising double-stranded DNA molecules and methods of use thereof
WO2023165530A1 (zh) 提高rna分子的胞内翻译效率和/或稳定性的方法
CN119709744A (zh) 一种激活p21基因表达的方法
Kojima et al. Development of gapmer antisense oligonucleotide with deoxyribonucleic guanidine (DNG) modifications
CA2289907C (en) Eukaryotic and retroviral antisense initiator elements
JP4701405B2 (ja) 核酸酵素複合体
Ai et al. Aptazyme-directed A-to-I RNA editing
Morita et al. Regulation of Gene Expression Using dCas9-SunTag